300 related articles for article (PubMed ID: 38233099)
1. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
2. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
Nguyen LS; Bretagne M; Arrondeau J; Zahr N; Ederhy S; Abbar B; Pinna B; Allenbach Y; Mira JP; Moslehi J; Rosenzwajg M; Salem JE
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383117
[TBL] [Abstract][Full Text] [Related]
3. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
Mir R; Shaw HM; Nathan PD
Melanoma Res; 2019 Feb; 29(1):102-106. PubMed ID: 30395075
[TBL] [Abstract][Full Text] [Related]
9. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
[TBL] [Abstract][Full Text] [Related]
10. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
[TBL] [Abstract][Full Text] [Related]
11. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
12. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Jespersen MS; Fanø S; Stenør C; Møller AK
Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
[TBL] [Abstract][Full Text] [Related]
13. Check this out: treatment paradigms in immune-checkpoint inhibitor colitis.
Kiparizoska S; Murphy ME; Mattar MC
Curr Opin Gastroenterol; 2023 Jan; 39(1):43-49. PubMed ID: 36504035
[TBL] [Abstract][Full Text] [Related]
14. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
Friedman CF; Proverbs-Singh TA; Postow MA
JAMA Oncol; 2016 Oct; 2(10):1346-1353. PubMed ID: 27367787
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
16. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
17. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
18. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
19. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Smajlović H; Prohić A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
[TBL] [Abstract][Full Text] [Related]
20. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]